Gadoxetic acid

Gadoxetic acid
Clinical data
Trade names	Eovist
Other names	Gadoxetate disodium (USAN US)
AHFS/Drugs.com	International Drug Names
ATC code	V08CA10 (WHO) ;
Legal status
Legal status	US: ℞-only; EU: Rx-only;
Identifiers
	IUPAC name 2-[[2-[bis(2-oxido-2-oxoethyl)amino]-3-(4-ethoxyphenyl)propyl]-[2-[bis(2-oxido-2-oxoethyl)amino]ethyl]amino]acetate; gadolinium(+3) cation;
CAS Number	135326-11-3 ;
PubChem CID	131704314;
DrugBank	DB08884 ;
ChemSpider	189907;
UNII	3QJA87N40S;
KEGG	D08008 ; D04288;
ChEMBL	ChEMBL1201768 ;
CompTox Dashboard (EPA)	DTXSID90928961 ;
Chemical and physical data
Formula	C23H30GdN3O11
Molar mass	681.75 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCOc1ccc(cc1)C[C@@H](CN(CCN(CC(=O)O)CC(=O)[O-])CC(=O)[O-])N(CC(=O)O)CC(=O)[O-].[Gd+3];
	InChI InChI=1S/C23H33N3O11.Gd/c1-2-37-18-5-3-16(4-6-18)9-17(26(14-22(33)34)15-23(35)36)10-24(11-19(27)28)7-8-25(12-20(29)30)13-21(31)32;/h3-6,17H,2,7-15H2,1H3,(H,27,28)(H,29,30)(H,31,32)(H,33,34)(H,35,36);/q;+3/p-3/t17-;/m0./s1; Key:PCZHWPSNPWAQNF-LMOVPXPDSA-K;
	(what is this?) (verify)

Gadoxetic acid is a gadolinium-based MRI contrast agent.^[3] Its salt, gadoxetate disodium, is marketed as Primovist in Europe and Eovist in the United States by Bayer HealthCare Pharmaceuticals.^[1]^[4]

Medical uses[edit]

It is used to increase the T1 signal intensity while imaging the liver lesions such as benign cysts, hemangioma, and liver cancer. It is excreted into bile by active secretion.^[5]

Pharmacokinetics[edit]

In those with end-stage renal failure, the clearance rate is only 17% with terminal half-life of 12 times longer than those with normal renal function.^[5]

References[edit]

^ ^a ^b "Eovist- gadoxetate disodium injection, solution". DailyMed. National Library of Medicine, National Institutes of Health, U.S. Health & Human Services. Retrieved 21 April 2021.
^ "Active substance(s): gadoxetic acid disodium" (PDF). List of nationally authorised medicinal products. European Medicines Agency. 14 January 2021.
^ Koh DM, Ba-Ssalamah A, Brancatelli G, Fananapazir G, Fiel MI, Goshima S, et al. (August 2021). "Consensus report from the 9th International Forum for Liver Magnetic Resonance Imaging: applications of gadoxetic acid-enhanced imaging". European Radiology. 31 (8): 5615–5628. doi:10.1007/s00330-020-07637-4. PMC 8270799. PMID 33523304.
^ "Eovist - Homepage". Archived from the original on 2009-04-25. Retrieved 2009-03-22.
^ ^a ^b "Clinical pharmacology and biopharmaceutics review" (PDF). Center for drug evaluation and research. Archived from the original (PDF) on 12 May 2021. Retrieved 15 December 2022.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

[Eovist_FDA_label-1] "Eovist- gadoxetate disodium injection, solution". DailyMed. National Library of Medicine, National Institutes of Health, U.S. Health & Human Services. Retrieved 21 April 2021.

[2] "Active substance(s): gadoxetic acid disodium" (PDF). List of nationally authorised medicinal products. European Medicines Agency. 14 January 2021.

[Koh_2021-3] Koh DM, Ba-Ssalamah A, Brancatelli G, Fananapazir G, Fiel MI, Goshima S, et al. (August 2021). "Consensus report from the 9th International Forum for Liver Magnetic Resonance Imaging: applications of gadoxetic acid-enhanced imaging". European Radiology. 31 (8): 5615–5628. doi:10.1007/s00330-020-07637-4. PMC 8270799. PMID 33523304.

[bayer-4] "Eovist - Homepage". Archived from the original on 2009-04-25. Retrieved 2009-03-22.

[FDA-5] "Clinical pharmacology and biopharmaceutics review" (PDF). Center for drug evaluation and research. Archived from the original (PDF) on 12 May 2021. Retrieved 15 December 2022.

[1]

[2]

[3]

[4]

[5]